Targeting De Novo Lipogenesis and Cholesterol Biosynthesis Simultaneously is a Novel Therapeutic Option for...

Area of Science:

• Oncology
• Molecular Biology
• Metabolic Research

Background:

• Hepatocellular carcinoma (HCC) presents limited treatment options globally.
• Altered lipid metabolism, particularly de novo lipogenesis, is a hallmark of HCC.
• Fatty acid synthase (FASN), the key enzyme in de novo lipogenesis, is implicated in HCC progression.

Purpose of the Study:

• To investigate the role of FASN in HCC development using a mouse model.
• To explore the interplay between de novo lipogenesis and cholesterol biosynthesis pathways in HCC.
• To identify novel therapeutic targets for HCC.

Main Methods:

• Utilized a hepatocellular carcinoma (HCC) mouse model.
• Investigated the function of Fatty Acid Synthase (FASN).
• Analyzed the crosstalk between de novo lipogenesis and cholesterol biosynthesis pathways.

Main Results:

• Loss of FASN partially suppresses HCC cell growth but does not prevent tumor formation.
• Evidence suggests alternative mechanisms support HCC growth independently of de novo lipogenesis.
• Identified a significant crosstalk between de novo lipogenesis and cholesterol biosynthesis in HCC.

Conclusions:

• Simultaneous inhibition of de novo lipogenesis and cholesterol biosynthesis presents a promising therapeutic strategy for HCC.
• Targeting both pathways may overcome resistance mechanisms in HCC treatment.
• This dual-targeting approach offers potential for both HCC prevention and therapy.